

March 25, 2026

The Honorable Jeanne Shaheen
United States Senate
506 Hart Senate Office Building
Washington, DC 20510

The Honorable Susan Collins
United States Senate
413 Dirksen Senate Office Building
Washington, DC 20510

The Honorable Raphael Warnock
United States Senate
717 Hart Senate Office Building
Washington, DC 20510

The Honorable John Kennedy
United States Senate
437 Russell Senate Office Building
Washington, DC 20510

Dear Senators Shaheen, Collins, Warnock, and Kennedy:

On behalf of the Endocrine Society, the world's largest professional organization of endocrinologists, thank you for introducing the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act of 2026. We are pleased to endorse this historic legislation and applaud your work to address this issue. The Society has over 18,000 members world-wide composed of scientists, physicians, nurses, and students, many with expertise in caring for people with diabetes. For years our members have expressed their alarm about the lack of access to affordable insulin. Consequently, improving insulin access and affordability is a top priority for the Endocrine Society and we commend you for your commitment to finding a solution that will address out-of-pocket costs for those with private insurance and those who are uninsured.

Insulin is a lifesaving drug for millions of Americans living with diabetes. For all people living with type 1 diabetes, insulin is the only option and must be taken for life. In the United States over 8.4 million people use insulin to manage their diabetes and avoid life-changing complications such as dialysis, heart disease, and amputation. Insulin was discovered over 100 years ago, and newer versions of the medication were developed almost 30 years ago. Despite these important milestones, this medication continues to be unaffordable for many people living with diabetes. Data shows that [in 2024](#) one in four people rationed their insulin due to cost – a rate that was unchanged from 2017.

The INSULIN Act will take meaningful steps to lower the out-of-pocket cost of insulin for people living with diabetes. The legislation will expand the \$35 monthly cap on out-of-pocket insulin costs, currently available for Medicare beneficiaries, to the private insurance market. This will expand the monthly co-pay cap to many individuals under the age of 65 who do not qualify for Medicare. The legislation takes steps to provide affordable insulin to uninsured Americans. The bill establishes a competitive grant



program that would provide 10 states with funds to create programs to provide insulin to uninsured individuals. The bill creates an insulin resource center and hotline for people with diabetes who are uninsured to connect them with resources to help them secure insulin. The legislation would also ensure that patients can share in any rebates and discounts on insulin that are normally collected by Pharmacy Benefit Managers. Finally, the bill includes provisions to promote biosimilar competition in the insulin market.

We stand ready to work with you to pass this critically important legislation without delay. This legislation will change and save lives, and we will work to help get this legislation to the president's desk for his signature as soon as possible because people with diabetes cannot wait any longer.

On behalf of our patients, thank you again for your leadership in introducing this important bipartisan legislation. We applaud your commitment to the millions of American who rely on insulin to survive. If we can be of any further assistance, please contact Rob Goldsmith, Director of Advocacy and Policy at rgoldsmith@endocrine.org.

Sincerely,

Robert Lash, MD
Chief Medical Officer